Metastasis-free survival of uveal melanoma by tumour size category based on The Cancer Genome Atlas (TCGA) classification in 1001 cases.

IF 4.9 2区医学 Q1 OPHTHALMOLOGY

Clinical and Experimental Ophthalmology Pub Date : 2024-10-04 DOI:10.1111/ceo.14446

Rolika Bansal, Hidayet Sener, Arupa Ganguly, Jerry A Shields, Carol L Shields

{"title":"Metastasis-free survival of uveal melanoma by tumour size category based on The Cancer Genome Atlas (TCGA) classification in 1001 cases.","authors":"Rolika Bansal, Hidayet Sener, Arupa Ganguly, Jerry A Shields, Carol L Shields","doi":"10.1111/ceo.14446","DOIUrl":null,"url":null,"abstract":"Background: Uveal melanoma (UM) can be classified by tumour size category and by The Cancer Genome Atlas (TCGA) groups (cytogenetic-based, 4-category prognostic classification into Groups A-D). This study was conducted to assess impact on metastasis-free survival (MFS) in UM by tumour size category based on correlation with TCGA classification.Methods: Retrospective analysis of 1001 cases categorised as small (0.0-3.0 mm), medium (3.1-8.0 mm) and large (≥8.1 mm), grouped by TCGA classification.Results: Of 1001 cases, TCGA Groups (A/B/C/D) included small (n = 270, 75%/11%/13%/1%), medium (n = 503, 46%/14%/27%/13%) and large (n = 228, 23%/19%/38%/20%) UM. The 5-and 10-year Kaplan-Meier MFS for small UM revealed Group A (98%, 98%), Group B (100%, 100%), Group C (86%, NA) and Group D (100%, NA). For medium UM, the values dropped with Group A (95%, 93%), Group B (90%, 90%), Group C (68%, 38%), and Group D (44%, NA). For large UM, the values dropped further with Group A (94%, 86%), Group B (85%, NA), Group C (40%, 28%), and Group D (23%, NA). Additionally, a comparison (small vs. medium vs. large tumour size category) revealed TCGA low-risk grouping (Groups A or B) in 86% vs. 60% vs. 58% cases with UM.Conclusion: By tumour size category, favourable cytogenetics (Groups A or B) is found in 86% of small tumours, 60% of medium tumours, and 58% of large tumours. The MFS at 10 years for favourable cytogenetics was 98% for small tumours, 92% for medium tumours, and 54% for large tumours. Tumour size category can serve as a surrogate for TCGA.","PeriodicalId":55253,"journal":{"name":"Clinical and Experimental Ophthalmology","volume":" ","pages":""},"PeriodicalIF":4.9000,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/ceo.14446","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Uveal melanoma (UM) can be classified by tumour size category and by The Cancer Genome Atlas (TCGA) groups (cytogenetic-based, 4-category prognostic classification into Groups A-D). This study was conducted to assess impact on metastasis-free survival (MFS) in UM by tumour size category based on correlation with TCGA classification.

Methods: Retrospective analysis of 1001 cases categorised as small (0.0-3.0 mm), medium (3.1-8.0 mm) and large (≥8.1 mm), grouped by TCGA classification.

Results: Of 1001 cases, TCGA Groups (A/B/C/D) included small (n = 270, 75%/11%/13%/1%), medium (n = 503, 46%/14%/27%/13%) and large (n = 228, 23%/19%/38%/20%) UM. The 5-and 10-year Kaplan-Meier MFS for small UM revealed Group A (98%, 98%), Group B (100%, 100%), Group C (86%, NA) and Group D (100%, NA). For medium UM, the values dropped with Group A (95%, 93%), Group B (90%, 90%), Group C (68%, 38%), and Group D (44%, NA). For large UM, the values dropped further with Group A (94%, 86%), Group B (85%, NA), Group C (40%, 28%), and Group D (23%, NA). Additionally, a comparison (small vs. medium vs. large tumour size category) revealed TCGA low-risk grouping (Groups A or B) in 86% vs. 60% vs. 58% cases with UM.

Conclusion: By tumour size category, favourable cytogenetics (Groups A or B) is found in 86% of small tumours, 60% of medium tumours, and 58% of large tumours. The MFS at 10 years for favourable cytogenetics was 98% for small tumours, 92% for medium tumours, and 54% for large tumours. Tumour size category can serve as a surrogate for TCGA.

查看原文本刊更多论文

根据癌症基因组图谱（TCGA）分类，按肿瘤大小分类的 1001 例葡萄膜黑色素瘤无转移生存率。

背景：葡萄膜黑色素瘤（UM）可按肿瘤大小类别和癌症基因组图谱（TCGA）组别（基于细胞遗传学的4类预后分类，分为A-D组）进行分类。本研究根据肿瘤大小类别与TCGA分类的相关性，评估无转移生存率（MFS）对UM的影响：方法：对1001例病例进行回顾性分析，按TCGA分类法分为小肿瘤（0.0-3.0毫米）、中肿瘤（3.1-8.0毫米）和大肿瘤（≥8.1毫米）：在1001个病例中，TCGA组（A/B/C/D）包括小型（n = 270，75%/11%/13%/1%）、中型（n = 503，46%/14%/27%/13%）和大型（n = 228，23%/19%/38%/20%）UM。小型 UM 的 5 年和 10 年 Kaplan-Meier MFS 显示，A 组（98%，98%）、B 组（100%，100%）、C 组（86%，NA）和 D 组（100%，NA）。中型 UM 的数值有所下降，A 组（95%，93%）、B 组（90%，90%）、C 组（68%，38%）和 D 组（44%，NA）。对于大型 UM，A 组（94%，86%）、B 组（85%，NA）、C 组（40%，28%）和 D 组（23%，NA）的数值进一步下降。此外，通过比较（小型肿瘤与中型肿瘤与大型肿瘤）发现，86%的 UM 病例与 60% 的 UM 病例与 58% 的 UM 病例属于 TCGA 低风险组（A 组或 B 组）：按肿瘤大小分类，86%的小型肿瘤、60%的中型肿瘤和58%的大型肿瘤的细胞遗传学状况良好（A组或B组）。细胞遗传学良好的小型肿瘤 10 年生存率为 98%，中型肿瘤为 92%，大型肿瘤为 54%。肿瘤大小类别可作为 TCGA 的替代指标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and Experimental Ophthalmology 医学-眼科学

CiteScore

7.60

自引率

12.50%

发文量

150

审稿时长

4-8 weeks

期刊介绍： Clinical & Experimental Ophthalmology is the official journal of The Royal Australian and New Zealand College of Ophthalmologists. The journal publishes peer-reviewed original research and reviews dealing with all aspects of clinical practice and research which are international in scope and application. CEO recognises the importance of collaborative research and welcomes papers that have a direct influence on ophthalmic practice but are not unique to ophthalmology.